Study of LW402 in Moderate-to-Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL

Enrollment

144

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

September 25, 2024

Study Completion Date

February 13, 2025

Conditions

Atopic Dermatitis (AD)

Interventions

DRUG

LW402

LW402 tablets

DRUG

LW402 placebo

LW402 placebo tablets

Trial Locations (1)

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Shanghai Longwood Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT07186387 - Study of LW402 in Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter